BACKGROUND: Open-label, single-centre Phase II trial evaluating the toxicity and antitumour activity of weekly docetaxel in the second-line management of advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Treatment comprised docetaxel 35 mg/m2 weekly for 6 weeks followed by 2 weeks' rest for a maximum of 3 cycles. RESULTS: Thirty-six patients received 220 weekly doses of docetaxel. Toxicity was generally mild: no grade 3-4 haematological toxicity; one grade 4 non-haematological event (bloody diarrhoea in a patient with pre-existing colon diverticulitis). Nausea (11%) and asthenia (8%) constituted the main grade 3 non-haematological toxicities. The objective response rate was 11% (14% minor response, 25% stable disease) and the median duration of survival upon the initiation of docetaxel was 160 days, with a 1-year survival rate of 23%. CONCLUSION: Docetaxel is active and well tolerated in the second-line treatment of advanced NSCLC and appears to yield an improved therapeutic index versus 3-weekly regimens.
BACKGROUND: Open-label, single-centre Phase II trial evaluating the toxicity and antitumour activity of weekly docetaxel in the second-line management of advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Treatment comprised docetaxel 35 mg/m2 weekly for 6 weeks followed by 2 weeks' rest for a maximum of 3 cycles. RESULTS: Thirty-six patients received 220 weekly doses of docetaxel. Toxicity was generally mild: no grade 3-4 haematological toxicity; one grade 4 non-haematological event (bloody diarrhoea in a patient with pre-existing colon diverticulitis). Nausea (11%) and asthenia (8%) constituted the main grade 3 non-haematological toxicities. The objective response rate was 11% (14% minor response, 25% stable disease) and the median duration of survival upon the initiation of docetaxel was 160 days, with a 1-year survival rate of 23%. CONCLUSION:Docetaxel is active and well tolerated in the second-line treatment of advanced NSCLC and appears to yield an improved therapeutic index versus 3-weekly regimens.
Authors: Hui Liu; Xu Zhang; Yevgeniy Y Vinogradskiy; Stephen G Swisher; Ritsuko Komaki; Joe Y Chang Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-27 Impact factor: 7.038
Authors: Jeroen J M A Hendrikx; Frederik E Stuurman; Ji-Ying Song; Vincent A de Weger; Jurjen S Lagas; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel; Jan H M Schellens; Serena Marchetti Journal: Pharmacol Res Perspect Date: 2020-08